A massive disruption now appears imminent in one of the world’s largest – and most important – industries.

In much the same way that Amazon disrupted the retail business – and how PayPal disrupted the payments industry – one under-the-radar health technology company now seeks to transform the $11.85 trillion global health industry.

By moving healthcare away from brick and mortar, traditional medicine into an AI-driven tool that offers unprecedented speed, efficiency, and accuracy…

Treatment.com (CSE: TRUE; OTC: TREIF) appears ready to change the face of medicine in a profound way.

Investors still have a brief window of opportunity to get in on this transformational investment opportunity while it still flies beneath Wall Street’s radar.

But as you’ll soon discover, this company’s technology is so powerful that it could become a valuable addition to hundreds of millions of households worldwide.

Consumers Are Increasingly Turning to Digital Technology to Manage Their Health

Whether most patients, providers, or large healthcare companies realize it or not, the healthcare industry is already in the early stages of significant change.

That’s because patients now desire access to more information – and better information – in the blink of an eye.

In a recent survey of U.S. health consumers, 71% reported facing major frustrations through their experience with healthcare providers. Concerns ranged from difficulties scheduling appointments to impersonal visits.

This means that the days of scheduling an appointment and spending hours in a doctor’s waiting room just to discuss a minor health issue could soon be long gone.

One billion people turn to Google each day to inquire about their health concerns. Wellness Apps were downloaded 1.2 billion times in 2020. And telemedicine grew 46% from 2019 to 2020.

And the Covid-19 pandemic only accelerated this change, as millions of patients adapted to telehealth and online options for healthcare faster than they had imagined they ever would.

Story continues

Just as consumers are more frequently reaching out and demanding more powerful, digital options to help manage their health…along comes Treatment.com.

Treatment.com (CSE: TRUE; OTC: TREIF) is a disruptive, forward-thinking healthcare technology company that is using the power of Artificial Intelligence to help consumers improve their health through personalized recommendations and insights.

Treatment.com is Making Better Information Available More Easily…So Patients Can Have Better Outcomes

For five years, Treatment.com’s global team of doctors and engineers worked to build and train a powerful Treatment Global Library of Medicine AI platform, so that it can think like a doctor and help consumers improve their health in a way far more efficient than traditional healthcare options.

Their program proved to be so effective that the University of Minnesota Medical School actually licensed it for the purposes of testing its medical students.

They spent over $10 million dollars – over five years – and worked with more than 100 doctors and 75 technical people to build the most personalized, intelligent healthcare AI on the planet.

Leading the effort to build this AI has been the company’s founder and CEO, John Fraser, a pioneer in the healthcare IT space who previously founded and led a healthcare IT company that was acquired for $1.2 billion.

In addition, the company’s technical team – responsible for building the AI – is led by some of Canada’s foremost experts on Artificial Intelligence and Machine Learning.

Treatment.com assembled the latest and best information possible into a global library of medicine, providing consumers with access to high-quality health information regardless of who they are or where they live.

The end result of this groundbreaking development is the company’s potentially disruptive new AI health assistant app, known as CARA.

Treatment’s Mobile App, in CARA is designed to give both caregivers and consumers the power to stay on top of their health and the health of their families.

Consumers are already turning to digital technology – in the form of Google searches or primitive health apps – to understand their general health and get answers to questions about their conditions.

Now… with the launch of CARA – Treatment.com (CSE: TRUE; OTC: TREIF) has hopes of permanently changing the access to healthcare for millions of patients.

In much the same way that consumers moved from brick-and-mortar shopping to the convenience and speed of Amazon…those patients seeking better healthcare solutions will now have access to a revolutionary new AI-driven platform.

Answers to health questions – and access to superior medical knowledge – are now available at your fingertips…24 hours a day, 7 days a week.

This is a true game-changer for the healthcare industry, as the global database of knowledge comes together with convenient, easy-to-use app technology – all driven by powerful AI that allows the consumer to have uninterrupted access to an app truly designed to “think like a doctor.”

CARA is unlike other healthcare apps in that it takes into consideration the medical history and individual characteristics of every person that can impact the likelihood of a disease. Factors that other online assessment tools simply ignore.

In addition, CARA learns from the consumer’s medical profile, wearable data and individual tracking data. CARA then leverages the insights and recommendations developed by the company’s proprietary AI to build easy and supportive tools to help ensure great health.

The CARA app also offers a comprehensive health and wellness tracking and analytics platform that integrates seamlessly with wearable devices (such as Apple Watch or Fitbit) so the company can seek to efficiently capitalize on the multi-trillion-dollar wellness industry.

CARA allows consumers to…

  • Keep Track of Loved Ones – Manage multiple profiles from a single account and easily keep track of family.

  • Manage Intelligent Follow-Ups – CARA will follow up to make sure the consumer is staying on top of symptoms and provide access to the latest prevention insights and tips.

  • Share the Knowledge – At any time, a patient can take their health assessment to their family doctor or other healthcare provider.

  • Track Symptoms – Track a symptom or medical condition over time to see how things have changed and stay on top of health concerns.

Treatment.com Partners with MentorMate to Create the Future of Healthcare AI

Just recently – on September 15 – Treatment.com (CSE: TRUE; OTC: TREIF) took another significant step toward making CARA available to hundreds of millions of consumers.

That’s the date that the company announced the consolidation of its advanced AI development capabilities with MentorMate, a leading healthcare software development firm based in the United States.

MentorMate is a global leader in mobile application development, with over 700 developers in the United State and the EU. Headquartered in Minneapolis near Treatment’s US operations, MentorMate specializes in advanced solutions for leading health care organizations.

With over 19 years in business and over 1,400 completed projects, MentorMate has the experience and scale to support rapidly expanding products – which makes the company ideal to team up with Treatment.com.

This exciting new collaboration consolidates the expertise of Treatment.com’s Global Library of Medicine, as well as support and maintenance of Cara, with MentorMate’s expertise. Together, these two companies have the depth and experience to support Treatment.com’s world-class medical AI products.

MentorMate’s proven track record in delivering high-quality health care software demonstrates they have the experience to deliver and support Treatment.com’s growing portfolio of healthcare solutions.

Multiple Revenue Streams Could Mean High Upside Potential for Treatment.com (CSE: TRUE) Investors

Of course, building a great AI platform – and bringing to market a powerful app such as CARA – is only part of the equation for Treatment.com (CSE: TRUE)(OTC:TREIF).

When evaluating the company’s investment potential, it’s important to see a clear, consistent path toward revenue. And in the case of Treatment.com, the company has three distinct revenue streams that add to its attractiveness:

Revenue Stream #1: Mobile App SubscriptionsTreatment.com’s (CSE: TRUE; OTC: TREIF) CARA app provides health insights and recommendations that offer deep consumer value. Consumers have demonstrated their willingness to pay for useful mobile wellness apps, and Treatment.com’s app is positioned well thanks to its powerful, proprietary AI platform.

Revenue Stream #2: Health & Wellness Platform – The second revenue stream involves Treatment.com’s leveraging of its health knowledge to recommend paid products and services to consumers. These can include telemedicine, clinics, pharmacies, wellness practitioners, and health products.

Revenue Stream #3: Clinical & Academic Applications – The company plans to leverage its AI for products in the medical industry, including university medical school training, as has already been done at the University of Minnesota Medical School. In addition, Treatment.com’s AI allows for integration with health clinics, resulting in more efficient, accurate healthcare visits.

On top of those initial projected revenue streams, the potential value of the patient insights and data collected by the company’s app could also have enormous value for third parties such as insurance providers, doctors’ offices, and government entities.

Access to this health data will provide deep insights, trends, and predictions that could allow these providers to provide better, more impactful health services on a broad scale.

Treatment.com is Led by an Expert Medical and Technical Team

In order for a healthcare technology company to be successful, it’s essential for it to have access to the most experienced, intelligent technical and medical minds available.

And that’s precisely the type of expertise Treatment.com (CSE: TRUE; OTC: TREIF) has assembled with its leadership team.

The company’s founder and CEO, John Fraser, is a software and technology expert who has built and sold several healthcare software companies. His first company, Ability Networks, was purchased by Inovalon for $1.2 billion.

Chief Medical Officer Dr. Kevin Peterson is a true pioneer in the industry, with 35 years of experience as a professor at the University of Minnesota. He has been the Principal Investigator (PI) or site-PI on many National Institutes of Health-funded studies, and the creation of an international electronic surveillance and research infrastructure.

Chief Innovation Officer Dr. Rob Scott is the founder of Remedy, an allied healthcare professional online consulting company. Dr. Scott has been doing informatics research for over 20 years, specializing in the area of patient self-care, developing technologies that support patient empowerment.

Director of Machine Learning Research Dr. Martin Michalowski is a leading expert in automated reasoning. He is co-founder of two technology-based companies and the tech lead of another. And he is the organizing chair of the Expanding the Boundaries of Health Informatics using Artificial Intelligence (HIAI) workshop held at the Association for the Advancement of Artificial Intelligence (AAAI) conference

Statistician and Data Scientist Dr. Ray Artz has advanced degrees in Mathematics and Statistics and 30 years’ experience in the Defense Industry. And he has served as a System Analyst, Computer System Architect, and Software Developer for numerous development projects including the NEXRAD Doppler Weather Radar System and the F-35 Lightning II Joint Strike Fighter.

And Director of AI Research Dr. David Poole is a Fellow of the Association for the Advancement of Artificial Intelligence (AAAI) and the winner of the Canadian AI Association (CAIAC) 2013 Lifetime Achievement Award.

Treatment.com Appears to Be an Undervalued, Under-the-Radar Opportunity Worthy of Serious Consideration

When compared with other companies in the space – many of which are still privately held – Treatment.com (CSE: TRUE; OTC: TREIF) appears to offer investors an attractive, investment opportunity in a company that has the potential for significant growth in valuation.

It appears that Treatment.com could have significant upside potential based solely on the valuations of its competitors (see chart above.)

But the true potential of this opportunity could reach far beyond such comparables due to the big tech platform built by doctors for doctors on a global scale

This is a company that appears to be on the verge of bringing massive disruption to the $11.85 trillion healthcare industry…at the precise time when consumers are demanding just such a disruption.

With a powerful, easy-to-use app – driven by its proprietary AI – Treatment.com is bringing consumers the type of improved healthcare access they’ve been searching for.

Opportunities for true disruption – as seen with companies like Amazon, PayPal, and Netflix – are truly rare.

It’s almost impossible to think of a world before those companies transformed their industries…just as it may soon be impossible to think back to the days of our outdated, inefficient healthcare system.

Treatment.com (CSE: TRUE; OTC: TREIF) offers the potential to bring an Amazon-style disruption to the healthcare industry at precisely the right time. This is one to keep a close eye on.

Other healthcare providers and pharmaceutical companies making major waves:

Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company that develops medicines to treat rare diseases. The company was founded in 2003 by Dr. Jeffrey Cohen, who had previously discovered the first approved treatment for acute lymphoblastic leukemia (ALL). Sage Therapeutics has since gone on to create treatments for other cancers and genetic disorders, including Pompe disease, Sanfilippo syndrome type A, Fabry disease and Gaucher disease. These therapies have been approved in over 40 countries around the world and are changing lives every day.

Sage Therapuetics is a fantastic example of a company using its resources to tackle the growing mental health crisis in the United States and abroad. With a focus on exciting new ways to treat mental health disorders, the company released the only FDA-approved treatment for post-partum depression. It's drug, Zulresso, soared through clinical trials with no issues, and is advertised to help mothers feel better in just 2.5 days. The drug is administered under the careful guidance of professionals in their specialized treatment centers and has been a huge success for the company.

But that’s not all it’s working on. Another drug in Sage’s pipeline is Zuranolone, which seeks to treat major depressive disorder and even treatment resistant depressive disorders. The drug is already in phase three of testing and could potentially provide help for patients who have previously struggled to find a medication that works for them.

Cassava Sciences (NASDAQ:SAVA) is a company that aims to make life-saving diagnostics and vaccines affordable and easily accessible for people in need. They believe all lives matter, and they are committed to saving as many lives as possible by making their products available to those who can't afford them. Cassava Sciences has two major projects: The first is their proprietary vaccine-making technology called "Cassava Plant Technology" (CPT), which allows us to use the cassava plant as an inexpensive seed starter platform for producing vaccines that would otherwise be too expensive or difficult to manufacture due to biosafety concerns. Second, they have developed a process of manufacturing diagnostic kits locally at very low cost.

Cassava Sciences is another company making major waves in the treatment of mental health, in particular, Alzheimer's disease. While its Sumifilam is still in its clinical trials, it's outlook is promising. The revolutionary new drug aims to help treat the devastating Alzheimer's disease by bringing together different proteins to interact properly.

Alzheimer’s affects over 5 million people in the United States alone, and it’s set to grow in the years ahead. And unfortunately, it’s incurable. Treatments such as these can offer a higher quality of life for patients suffering with the disease, and Cassava’s efforts could be life-changing.

Cassava has had an incredible year. And has continued to make headlines with new partnerships, grants, and deals. Thanks to its efforts, it has seen its share price skyrocket from just $2 last May to its current price of $37.50. That’s a 1775% return for early investors in this innovative company.

COMPASS Pathways plc (NASDAQ:CMPS) is an international company that provides engineering and construction services for the oil and gas industry. The company was founded in 2004, with headquarters in London, UK. Compass has a global presence: offices located in Houston, Texas; Aberdeen, Scotland; Kuwait City, Kuwait; Dubai and Khobar in the United Arab Emirates; Moscow Russia; Singapore and Kuala Lumpur Malaysia.

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is pioneering the development of a new model of psilocybin therapy, in which a proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and the company is currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. COMPASS’ meticulous approach to psilocybin treatments is important because, while legalization may look imminent, there’s still a long road ahead for this relatively new medicine.

"There simply isn't yet enough evidence of safety and efficacy of psilocybin therapy, which is why we're doing our trials," adding "the review and approval to regulatory agencies is really the best way ensure the safety, efficacy and quality of any medicine or therapy," CEO George Goldsmith explained.

Though the British company made its NYSE debut in September, COMPASS has made tremendous progress and has attracted a lot of attention along the way. Though its share price has fallen from its February highs, it is still one of the first-movers in the burgeoning psilocybin industry, which means there is still plenty of upside.

Neuronetics, Inc. (NYSE:STIM) is an industry leader in the development of neuromodulation therapies for neurological disorders and pain management. The company's products are based on a proprietary delivery platform that uses low-intensity electrical currents to stimulate nerve cells in the brain using electrodes on the surface of the head or via implanted leads directly into targeted areas of the nervous system. Neuronetics has developed both investigational devices and FDA-approved therapeutic devices for use in clinical trials, including deep brain stimulation (DBS) therapy for Parkinson’s disease, essential tremor, dystonia and other movement disorders; peripheral nerve field stimulation (PNFS) therapy for chronic neuropathic pain; vagus nerve stimulator therapy for epilepsy treatment-resistant depression among many others.

Neuronetics Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. The company’s first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.

Working with its NeuroStar therapy system, the company’s TouchStar protocol is a non-drug, non-invasive transcranial magnetic stimulation (TMS) treatment for Major Depressive Disorder (MDD). Greg Harper, Vice President of Product Development and Operations at Neuronetics, explained, The TouchStar protocol is particularly impactful when paired with our patented Contact Sensing precision technology that provides clinicians with the confidence of knowing they are giving patients the right dose at the exact location."

Though Neuronetics posted a third quarter loss, the company did, however, beat earnings estimates. And it has outperformed many of its peers this year, which is no small feat. Since falling to $1.46 in March, Neuronetics has seen its share price soar by 480%, rising to a yearly high of $8.51.

Acadia Healthcare Company, Inc. (NASDAQ:ACHC) offers a wide range of behavioral health and addiction services to its patients through the use of evidence-based treatment methods. The company is primarily focused on providing a continuum of care for individuals in need with mental health and substance abuse related issues by developing personalized treatment plans that are designed to meet the specific needs of each individual they serve, while also providing support for family members or friends who may be involved in their recovery process. Acadia Healthcare’s goal is to provide the best possible clinical outcomes along with improved quality of life for those it serves. In addition, this company seeks out opportunities to provide education about these conditions as well as resources that will help people live healthier lives free from stigma or prejudice.

sets itself apart from other companies in this list due to its approach to the mental health industry. It’s not a drug producer, but rather a treatment provider. Acadia is a multinational behavioral healthcare conglomerate with over 580 facilities across the United States and the United Kingdom. From psychiatric hospitals to residential treatment centers, the company is well-versed in the needs of patients in crisis, providing top-tier services for people suffering from a wide range of mental health issues.

Acadia has had a particularly strong year, rising over 20% since January alone. But that hardly compares to it’s 2020 showing. Acadia’s stock price was sitting at just $24 in May of 2020, and has since soared by nearly 200%, rising to its current price of $61. And with strong financials, the company’s share price could head even higher in the coming months.

Toronto-based Field Trip Health (CSE:FTRP) is taking a three-pronged approach in their work in the transformative psychedelic medicine sector. Not only are they involved in drug development, but they’re also involved in manufacturing and run a number of treatment clinics.

Field Trip has hit the ground running. With clinics currently operating in Toronto, Los Angeles, and New York, they have plans to ramp up to 75 clinics – providing psychotherapy along with psychedelic treatments. As one of the frontrunners in this exciting new industry, investors are keeping a close eye on Field Trip.

Trillium Therapeutics Inc. (TSX:TRIL) is a specialized biotechnology company that takes a unique approach on the industry, harnessing insights from nature to develop novel immunotherapies to treat cancer. Trillium’s products tackle such diseases as lymphoma and myeloma and other blood cancers.

Though Trillium is still young compared to some of its peers, the company has already carved out a name for itself in this industry. Though Trillium has faced some resistence this year, the company still has a ton of potential, and lots of exciting new developments in its pipeline.

Oncolytics Biotech Inc. (TSX:ONC) is another Canadian biotech firm. The company got it start from a major series of discoveries based out of the University of Calgary and has grown significantly over the past two decades. Onoclytics’ primary product is REOLYSIN, a first-in-class, systemically administered, immuno-oncolytic virus created with the potential to act as a therapy for cancer patients.

Namaste Technologies Inc (TSX.V:N) through its subsidiaries, operates as a retailer of a variety of marijuana products, including vaporizers and other smoking accessories. The company sells its goods through e-commerce sites operating in 26 countries. In addition to its accessory business, Namaste also engages in product development and the distribution of medical cannabis products in Canada.

This month, Namaste announced that it will be taking 100% ownership of CannMart Labs. Meni Morim, Chief Executive Officer of Namaste, noted of the transaction, "Acquiring the remaining interest in CannMart Labs is another important milestone achieved in establishing Namaste as a leading company within the Canadian cannabis sector,"

The Hexo Corporation (TSX:HEXO), as previously mentioned, made major waves with its partnership with Molson Coors to develop cannabis beverages. In Hexo’s fourth-quarter press release, the company shared some optimistic news regarding Truss’ progress, with Sebastien St-Louis, Hexo CEO and co-founder, explaining, “We are commanding significant market share in Quebec and this year we made major strides by launching Truss cannabis infused beverages in Canada in addition to our initial foray into the U.S. with Molson Coors, a world-class partner,”

The world is currently in the midst of a mental health crisis. Everything that could possibly go wrong, has. And to make matters worse, millions, if not tens of millions of people are stuck in isolation. It's never been more important to support the field of mental health. And the FDA seems to agree. Not only have they fast-tracked psilocybin, they've also approved other exciting new approaches to tackling mental health issues.

By Charles Kennedy


PAID ADVERTISEMENT. This article is a paid advertisement. Advanced Media Solutions Ltd. and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Treatment.com International, Inc. Inc. (“Treatment.com” or “Company”) to conduct investor awareness advertising and marketing. Treatment.com paid the Publisher to produce and disseminate six articles profiling the Company at a rate of seventy-five thousand US dollars per article. This compensation should be viewed as a major conflict with our ability to be unbiased.

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by Treatment.com) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.

SHARE OWNERSHIP. The Publisher owns shares and / or options of the featured company and therefore has an additional incentive to see the featured company’s stock perform well. The Publisher does not undertake any obligation to notify the market when it decides to buy or sell shares of the issuer in the market. The Publisher will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.

FORWARD LOOKING STATEMENTS. This publication contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward looking statements in this publication include, but are not limited to, the size and anticipated growth of the market for the company’s products, the anticipated growth of the market for AI-assisted products generally, the anticipated growth of the market for app-based products generally, the anticipated launch date for the company’s products, the anticipated growth of the market for health care app-based products generally, the anticipated launch date for the company’s products, and the anticipated growth and expansion of the medical library to which the company’s products have access. Factors that could cause results to differ include, but are not limited to, the companies’ ability to fund its capital requirements in the near term and long term, the management team’s ability to effectively execute its strategy, the degree of success of the AI technology used in the company’s products, the company’s ability to effectively market the company’s products to customers within its three anticipated revenue streams, supply chain constraints, pricing pressures, etc. The forward-looking information contained herein is given as of the date hereof and we assume no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.

INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

TERMS OF USE. By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here http://oilprice.com/Terms-of-Use. If you do not agree to the Terms of Use http://oilprice.com/Terms-of-Use, please contact Advanced Media Solutions Ltd. to discontinue receiving future communications.

INTELLECTUAL PROPERTY. oilprice.com is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.

Read this article on OilPrice.com

(305) 707 0888